NEUROCRINE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEUROCRINE, and when can generic versions of NEUROCRINE drugs launch?
NEUROCRINE has two approved drugs.
There are thirty-one US patents protecting NEUROCRINE drugs.
There are three hundred and three patent family members on NEUROCRINE drugs in forty-three countries and nineteen supplementary protection certificates in sixteen countries.
Drugs and US Patents for NEUROCRINE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Neurocrine | ONGENTYS | opicapone | CAPSULE;ORAL | 212489-002 | Apr 24, 2020 | RX | Yes | Yes | 9,745,290 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-001 | Apr 11, 2017 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-003 | Apr 23, 2021 | RX | Yes | No | 11,439,629 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | 10,952,997 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Neurocrine | INGREZZA | valbenazine tosylate | CAPSULE;ORAL | 209241-002 | Oct 4, 2017 | AB | RX | Yes | Yes | 11,439,629 | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for NEUROCRINE Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5290185 | ⤷ Try a Trial |
Denmark | 2481410 | ⤷ Try a Trial |
Singapore | 11201906883S | ⤷ Try a Trial |
Canada | 3051832 | ⤷ Try a Trial |
Morocco | 43116 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NEUROCRINE Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1907382 | C20160042 00214 | Estonia | ⤷ Try a Trial | PRODUCT NAME: OPIKAPOON;REG NO/DATE: EU/1/15/1066 28.06.2016 |
1907382 | CR 2016 00061 | Denmark | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/15/1066 20160628 |
1907382 | 93327 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: OPICAPONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/15/1066 - ONGENTYS - OPICAPONE |
2481410 | C02481410/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: OPICAPON; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66547 26.04.2018 |
1907382 | C 2016 044 | Romania | ⤷ Try a Trial | PRODUCT NAME: OPICAPONA SAU O SARE ACCEPTABILA FARMACEUTIC A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/15/1066; DATE OF NATIONAL AUTHORISATION: 20160624; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1066; DATE OF FIRST AUTHORISATION IN EEA: 20160624 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.